GlassScriptPhysician profile
Marshall C Hall
NPI 1881676484
$737.96
in general payments reported to CMS, 2019-2025
15 companies · $93.75 in 2025
The $93.75 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.47 · 2021: $34.85 · 2023: $21.64 · 2024: $542 · 2025: $93.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $657.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $164.13 | 2024-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $94.16 | 2024-2025 | Erleada |
| Boston Scientific Corporation | $80.44 | 2023-2024 | Spaceoar Vue System - 10ml |
| Bayer Healthcare Pharmaceuticals INC. | $65.27 | 2024-2025 | |
| Teleflex LLC | $64.23 | 2021-2024 | Urolift |
| Pfizer INC. | $47.55 | 2024-2025 | |
| Abbvie INC. | $46.98 | 2024 | |
| Endo USA, INC. | $28.20 | 2024 | Xiaflex, Aveed |
| Endo Pharmaceuticals INC. | $28.20 | 2024 | Aveed, Xiaflex, Edex |
| Merck Sharp & Dohme LLC | $27.07 | 2024 | Lynparza |
| Astellas Pharma US INC | $22.92 | 2019 | |
| Covidien LP | $22.55 | 2019 | |
| Urogen Pharma, INC. | $20.11 | 2024 | |
| Abc Home Medical Supply, INC. | $18.26 | 2024 | |
| Laborie Medical Technologies Corp. | $7.89 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.